Pharmaceuticals

Adial Pharmaceuticals

Adial Pharmaceuticals Announces Q3 2025 Financial Results and Advances AD04 Development

Adial Pharmaceuticals released FY2025 Q3 earnings on November 13, 2025 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -0.0808 (forecast USD -0.14)

Adial Pharmaceuticals released FY2025 9 Months earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -0.606

Jason McCarthy Gives Adial Pharmaceuticals a Buy Rating

Adial Pharmaceuticals released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1843 (forecast USD -0.22)

Adial Pharmaceuticals released FY2025 Semi-Annual Earnings on August 13 EST, with actual revenue of USD 0 and EPS of USD -0.4873

Adial Pharmaceuticals Announces Submission of Important Documents

Adial Pharmaceuticals signs AD04 production agreements with Cambrex and Thermo Fisher

Adial Pharmaceuticals' AD04 Phase III Clinical Trial Makes Progress

Adial Pharmaceuticals Registers About 6.73 Million Shares for Shareholder Resale

Adial Pharmaceuticals Reports Reduced Q1 Net Loss

Adial Pharmaceuticals released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3408 (forecast USD -0.495)

Adial Pharmaceuticals Inc Expected to Report Q1 EPS Loss of 49 Cents

Adial Pharmaceuticals Inc expects to report a loss of 49 cents per share

Adial Pharmaceuticals Granted FDA Approval to Hold End-of-Phase 2 Meeting

Adial Pharmaceuticals Conducts Warrant Transaction to Raise $2.75 Million

Adial Obtains Patent for AD04 to Treat Alcohol-Related Conditions

Adial Pharmaceuticals released FY2024 Q4 earnings on March 4, 2025 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.3227 USD (forecast -0.3433 USD)

Adial Pharmaceuticals released FY2024 earnings on March 4 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -2.7202 USD (forecast -2.79 USD)

Adial Pharmaceuticals Obtains New Patent, Expanding Treatment Methods for Alcohol Use Disorders

EKSO Bionics

Profusa

Antelope Enterprise

Cemtrex

FLY-E

Borealis Foods

Zhongchao

ON24

Aimei Health Tech

374Water

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap